to transform cancer therapy. Our novel Gammabody™ platform generates gamma delta bispecific T cell engager (bsTCE) therapeutics that activate a unique and relatively abundant effector gamma delta T cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T cells. This approach is designed to complement natural tumor recognition, direct Vγ9Vδ2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade. Our Gammabody™ drug candidates have, in preclinical studies, demonstrated potent, specific Vγ9Vδ2 T cell activation and killing of patient-derived tumor cells in preclinical studies. We expect that activation of adaptive immunity by our approach has the potential to provide durable immune responses with the potential of enhancing patient survival.